These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2930208)

  • 1. Cyclosporine in the treatment of psoriatic arthritis.
    Gupta AK; Matteson EL; Ellis CN; Ho VC; Tellner DC; Voorhees JJ; McCune WJ
    Arch Dermatol; 1989 Apr; 125(4):507-10. PubMed ID: 2930208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy.
    Salvarani C; Macchioni P; Boiardi L; Rossi F; Casadei Maldini M; Mancini R; Beltrandi E; Lodi L; Bisighini G; Portioli I
    J Rheumatol; 1992 Jan; 19(1):74-9. PubMed ID: 1556703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate treatment of psoriatic arthritis.
    Zachariae H; Zachariae E
    Acta Derm Venereol; 1987; 67(3):270-3. PubMed ID: 2442947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open study on the efficacy and safety of auranofin in treating psoriatic arthritis.
    Dequeker J; Gevers G
    Scand J Rheumatol Suppl; 1986; 63():85-95. PubMed ID: 3474779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
    Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
    Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriatic arthritis treated with oral colchicine.
    Seideman P; Fjellner B; Johannesson A
    J Rheumatol; 1987 Aug; 14(4):777-9. PubMed ID: 3668983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
    Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA
    Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [FDDF (fast dissolving dosage form) piroxicam for sublingual administration in the treatment of rheumatoid arthritis].
    Montecucco C; Caporali R; Ronchetti A; Rossi S; Comaschi E
    Minerva Med; 1994 Dec; 85(12):633-8. PubMed ID: 7854556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of etretinate in psoriatic arthritis.
    Klinkhoff AV; Gertner E; Chalmers A; Gladman DD; Stewart WD; Schachter GD; Schachter RK
    J Rheumatol; 1989 Jun; 16(6):789-91. PubMed ID: 2778761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tigason (etretinate) treatment in psoriatic arthritis.
    Ciompi ML; Bazzichi L; Marotta G; Pasero G
    Int J Tissue React; 1988; 10(1):25-7. PubMed ID: 3397251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose weekly oral methotrexate therapy for inflammatory arthritis.
    Boh LE; Schuna AA; Pitterle ME; Adams EM; Sundstrom WR
    Clin Pharm; 1986 Jun; 5(6):503-8. PubMed ID: 3720217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.
    Bongartz T; Coras B; Vogt T; Schölmerich J; Müller-Ladner U
    Rheumatology (Oxford); 2005 Jan; 44(1):126-9. PubMed ID: 15479756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of seronegative oligoarthritis with salazopyrine].
    Stroehmann I; Wüstenhagen E; Martini M
    Z Rheumatol; 1987; 46(2):79-82. PubMed ID: 2885989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
    Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
    Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Retinoid in the treatment of psoriatic arthropathy: a pilot study].
    Rosenthal M
    Schweiz Med Wochenschr; 1979 Dec; 109(48):1912-4. PubMed ID: 538432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose cyclosporine A in severe psoriasis.
    Marks J
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):68-71. PubMed ID: 3381305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study.
    Gottlieb AB; Kircik L; Eisen D; Jackson JM; Boh EE; Strober BE; Frankel E; Xia HA; Stevens SR
    J Dermatolog Treat; 2006; 17(6):343-52. PubMed ID: 17853307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.